Abstract
More than 80% of lung cancer is non-small cell lung cancer (NSCLC), and the epidermal growth factor receptor (EGFR)-mediated signaling pathway is closely related to the occurrence and development of NSCLC. Small molecule EGFR-tyrosine kinase inhibitors (EGFR-TKI) targeting EGFR have been used in the clinical treatment of NSCLC, and positron emission tomography/computed tomgraphy (PET/CT) imaging can noninvasively monitor the expression and mutation status of EGFR in patients with NSCLC. 18F-FDG PET/CT imaging has predictive value for the activation of EGFR mutation and EGFR-TKI treatment efficacy, and in vivo can be directly observed drugs and systemic tumor targeting EGFR combined with the specific circumstances, by PET/CT imaging before and after treatment, to achieve dynamic monitoring, guide the therapy before treatment and treatment of sensitive population screening process, to achieve NSCLC EGFR-TKI precise treatment is essential.